Literature DB >> 20164461

Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.

Rui Zhang1, Rong He, Jiang Qian, Jie Guo, Kang Xue, Yi-Fei Yuan.   

Abstract

PURPOSE. To evaluate the effects of intravitreal injection of liposomes encapsulating tacrolimus (FK506) on experimental autoimmune uveoretinitis (EAU) in Lewis rats. METHODS. Liposomes containing tacrolimus were prepared by reverse-phase evaporation vesicles. EAU was induced in Lewis rats by subcutaneous injection of interphotoreceptor retinoid-binding protein R16 peptide emulsified in adjuvant. Ten days later, rats were intravitreally injected with saline, tacrolimus, tacrolimus-loaded liposomes, or unloaded liposomes. Clinical signs of inflammation and ocular histologic sections were observed and graded. Retinal function was evaluated by electroretinography (ERG). Tacrolimus concentration was determined in the vitreous body and serum by ELISA. Ocular biodistribution of rhodamine-conjugated liposomes containing tacrolimus (tacrolimus-Rh-lip) was analyzed with a laser scanning confocal microscope. To evaluate the systemic effect of intravitreally injected tacrolimus, delayed-type hypersensitivity (DTH) and lymphocyte proliferation assay (LPA) responses were detected. RESULTS. Treatment of EAU with intravitreal injection of liposomal tacrolimus significantly reduced intraocular inflammation and markedly inhibited the development of EAU, as determined in clinical and histopathologic analyses. No toxic effects could be detected as evaluated by ERG. The concentration of tacrolimus in ocular fluids remained for as long as 14 days after liposomal injection of tacrolimus. Confocal microscopy showed a transretinal distribution of the liposomal particles. DTH and LPA responses were not impaired in liposomal tacrolimus-treated rats. CONCLUSIONS. Intravitreal injection of liposomal tacrolimus was highly effective in suppressing the process of EAU without any side effects on retinal function or systemic cellular immunity. This treatment may represent a new option for the management of intraocular inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164461     DOI: 10.1167/iovs.09-4373

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

Review 1.  [Use of nanoparticles in ophthalomology].

Authors:  I Hahn; P Heiduschka; E Endl; N Eter
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

Review 2.  Nanocarriers of nanotechnology in retinal diseases.

Authors:  Ali M Al-Halafi
Journal:  Saudi J Ophthalmol       Date:  2014-03-05

Review 3.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 4.  Nanomedicine in the application of uveal melanoma.

Authors:  Shuo You; Jing Luo; Hans E Grossniklaus; Ma-Ling Gou; Ke Meng; Qing Zhang
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

Review 5.  [Nanoparticles as drug delivery systems in ophthalmology].

Authors:  M Löscher; J Hurst; L Strudel; M S Spitzer; S Schnichels
Journal:  Ophthalmologe       Date:  2018-03       Impact factor: 1.059

Review 6.  Nanotechnology in retinal drug delivery.

Authors:  Sibo Jiang; Yesenia L Franco; Yan Zhou; Jianjun Chen
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

7.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

Review 8.  Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.

Authors:  Md Habban Akhter; Irfan Ahmad; Mohammad Y Alshahrani; Alhanouf I Al-Harbi; Habibullah Khalilullah; Obaid Afzal; Abdulmalik S A Altamimi; Shehla Nasar Mir Najib Ullah; Abhijeet Ojha; Shahid Karim
Journal:  Gels       Date:  2022-01-28

9.  Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models.

Authors:  Leslie Rebibo; Connie Tam; Yan Sun; Eve Shoshani; Amit Badihi; Taher Nassar; Simon Benita
Journal:  J Control Release       Date:  2021-03-30       Impact factor: 9.776

Review 10.  Liposomes and nanotechnology in drug development: focus on ocular targets.

Authors:  Miki Honda; Tomohiro Asai; Naoto Oku; Yoshihiko Araki; Minoru Tanaka; Nobuyuki Ebihara
Journal:  Int J Nanomedicine       Date:  2013-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.